



Jubilant Bhartia Group-Committed to improving lives in the United States

Jubilant Bhartia Group's three-decade-long strong relationship with the US has been nurtured mutually through trust, transparency and collaboration. Over the years, the conducive business environment in the United States has helped Jubilant to grow and diversify exponentially. Today the Group's engagement with the US spreads across various sectors - pharmaceuticals, research, chemicals, healthcare, aviation and several others. This nurturing partnership promises to deepen further and will be pivotal in defining growth for the Jubilant Bhartia Group and the US.



Corporate office at Yardley, Pennsylvania



Manufacturing facility in Salisbury, Maryland



Manufacturing facility in Spokane, Washington





At the forefront of innovation through its pharmaceuticals business



Playing a vital role in improving lives in the US



Firmly believes in the potential of collaboration and considers Unites States its significant ally



Network of 46 Radiopharmacies serving over 1700 hospitals across the US



Committed to strengthen presence in the United States with a vision to meet current and future medical needs



Committed to investing US \$285 Million to further expand its manufacturing footprint in collaboration with the US Government

2000

Employees to support US operations across multiple locations

A leader in innovation



Leader in cardiac imaging in the US through proprietary product RUBY-FILL

RUBY-FILL enhances how patients with known or suspected coronary artery disease are diagnosed and managed. Presence in the top 80% of cardiac networks in the US



Multiple products in clinical trials at various locations in the US, targeting unmet medical needs in oncology & autoimmune diseases



Clinical trials for I131-MIBG to treat Neuroblastoma, a paediatric tumour receiving over 800 (orphan drug) cases annually





Saving lives in the pandemic - strategic collaboration with five prominent pharmaceutical firms helped Jubilant in rapidly scaling-up production, ensuring a timely supply of COVID-19 drugs and vaccines in the United States



The sole provider of venom Immunotherapy in the US to treat life-threatening allergies. Invested in a state-of-the-art venom extraction facility and a team of experienced scientists



Contributes to US Government's strategy of strengthening supply chain resilience - One of the few Indian pharma companies manufacturing high-quality, affordable finished dosage formulations in the US



2500
Allergy Therapy practitioners catered in the country

Trusted partner for US brands expanding footprints in India





Customised its offerings to local taste buds



Partnered with Domino's, through its food service business, to transform India into the largest network of Domino's pizza outlets outside the US



Continues to build Domino's business internationally - Leadership positions in markets like Turkey, Sri Lanka and Bangladesh



POPEYES DUNKIN'







Successfully collaborated with other US brands accelerating their market penetration in India -Popeyes, Dunkin', Bell Helicopters, Textron Aviation & Transocean





Headquartered in India, Jubilant Bhartia Group has a strong presence in diverse sectors like Pharmaceuticals, Contract Research & Development Services, Proprietary Novel Drugs, Life Science Ingredients, Agri Products, Performance Polymers, Food Service (QSR), Food, Auto, Consulting in Aerospace and Oilfield Services.

The Group through its investments in India, USA, Canada, Europe, Singapore, Africa, Australia, China, Sri Lanka and Bangladesh employs a 46,000 strong workforce.



Jubilant Bhartia Group
Plot No. 1A, Sector 16A, Film City
Noida, Uttar Pradesh, India

